Department of Pharmacology, SVKM's Dr. Bhanuben Nanavati College of Pharmacy, Mumbai, India.
Immunopharmacol Immunotoxicol. 2021 Feb;43(1):8-21. doi: 10.1080/08923973.2020.1837867. Epub 2020 Oct 25.
Pneumonia of unknown etiology was detected in a few patients in Wuhan City, Hubei Province, China. The causative agent was named as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by the World Health Organization (WHO). The disease caused by this virus was named as a new coronavirus disease: COVID-19. The disease has a global impact affecting more than 200 nations including the USA, India, Brazil, Russia, and Peru are the 5 most severely affected nations. The discovery of the genotype and phenotype of SARS-CoV-2 boosted the global efforts for the development of treatment options and vaccines for the COVID-19. As the transmission of the virus is rapid, to protect the global population, the development of an effective vaccine against the virus is very essential. The current review highlights the various platforms and technologies used globally for the development of the vaccine and also focuses on the current status of the vaccine candidates under development by organizations to combat the global threat of COVID-19 pandemic.
在中国湖北省武汉市,少数患者被检测出不明原因肺炎。世界卫生组织(WHO)将其病原体命名为严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)。由该病毒引起的疾病被命名为新型冠状病毒病:COVID-19。该疾病具有全球性影响,影响包括美国、印度、巴西、俄罗斯和秘鲁在内的 200 多个国家,这 5 个国家受影响最严重。SARS-CoV-2 的基因型和表型的发现促进了全球开发 COVID-19 治疗选择和疫苗的努力。由于病毒传播迅速,为了保护全球人口,开发针对该病毒的有效疫苗非常重要。本综述重点介绍了全球用于开发疫苗的各种平台和技术,并关注了各组织为应对 COVID-19 大流行的全球威胁而开发的疫苗候选物的现状。